ENMD-2076
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Fallopian Cancer, Peritoneal Cancer
Trial Timeline
Apr 1, 2010 → Dec 1, 2012
NCT ID
NCT01104675About ENMD-2076
ENMD-2076 is a phase 2 stage product being developed by CASI Pharmaceuticals for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01104675. Target conditions include Ovarian Cancer, Fallopian Cancer, Peritoneal Cancer.
What happened to similar drugs?
11 of 20 similar drugs in Ovarian Cancer were approved
Approved (11) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02234986 | Phase 2 | Completed |
| NCT01639248 | Phase 2 | Completed |
| NCT01104675 | Phase 2 | Completed |
| NCT00904787 | Phase 1 | Completed |
| NCT00806065 | Phase 1 | Completed |
| NCT00658671 | Phase 1 | Completed |
Competing Products
20 competing products in Ovarian Cancer